Fundamentals Data provided by Morningstar.Data provided by Morningstar.
52 Week Range
Avg. Volume (1 month)
as at 24 Feb 3:44pm
2 ASX healthcare shares bucking the trend to hit new highs on Friday
Anteris (ASX:AVR) share price soars 22% on successful human trial
Why the Anteris (ASX:AVR) share price backtracked 6% today
Why is the Anteris (ASX:AVR) share price surging today?
Share Market News
Anteris (ASX:AVR) share price drops 7% despite positive announcement
Share Market News
The Anteris (ASX:AVR) share price is down today but has soared 150% in 3 months
Share Market News
Why the Anteris Technologies (ASX:AVR) share price soared 23% today
Share Market News
Why the Anteris (ASX:AVR) share price will be on watch today
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
|Date||Announcement||Price Sensitive?||Time||No. of Pages||File Size|
Formerly known as Admedus Ltd (ASX: AHZ), Anteris Technologies Ltd (ASX: AVR) is a healthcare company specialising in the design and production of heart valve and tissue products.
After having sold the rights to its CardioCel® and VascuCel® patch products in 2019, the company’s main focus today is on its Adapt® BioScaffold products and the development of new heart valve replacement solutions. According to Anteris, the Adapt products are used across more than 135 medical centres globally.
In 2020, the company commenced human trials of its DurAVR™ heart valve.
The Anteris share price has been a highly disappointing performer on the ASX, losing more than 90% of its value over the past five years. The company has executed several capital raisings and has struggled with debt and cash flow issues.
|09 Aug 2022||$26.00||$-1.16||-4.27%||35,662||$26.31||$26.31||$25.00|
|08 Aug 2022||$27.16||$-0.44||-1.59%||7,402||$27.90||$28.00||$26.31|
|05 Aug 2022||$27.60||$0.10||0.36%||7,385||$27.25||$27.88||$26.73|
|04 Aug 2022||$27.50||$1.40||5.36%||13,869||$26.36||$28.50||$25.99|
|03 Aug 2022||$26.10||$-0.19||-0.72%||9,397||$25.54||$26.61||$25.12|
|02 Aug 2022||$26.29||$-0.31||-1.17%||11,406||$26.64||$26.70||$25.14|
|01 Aug 2022||$26.60||$-0.55||-2.03%||7,999||$27.20||$27.23||$26.11|
|29 Jul 2022||$27.15||$1.05||4.02%||26,333||$26.00||$27.32||$26.00|
|28 Jul 2022||$26.10||$0.40||1.56%||11,582||$25.80||$26.10||$25.50|
|27 Jul 2022||$25.70||$0.61||2.43%||14,741||$25.09||$25.84||$24.00|
|26 Jul 2022||$25.09||$0.59||2.41%||9,013||$24.50||$25.19||$24.50|
|25 Jul 2022||$24.50||$-2.75||-10.09%||30,363||$26.44||$27.00||$23.71|
|22 Jul 2022||$27.25||$-0.20||-0.73%||10,172||$27.46||$27.89||$26.66|
|21 Jul 2022||$27.45||$0.95||3.58%||18,099||$26.50||$27.94||$26.40|
|20 Jul 2022||$26.50||$0.35||1.34%||31,394||$26.50||$26.70||$26.01|
|19 Jul 2022||$26.15||$-0.08||-0.30%||5,135||$26.60||$26.60||$26.02|
|18 Jul 2022||$26.23||$-0.59||-2.20%||5,814||$26.90||$26.90||$26.23|
|15 Jul 2022||$26.82||$0.82||3.15%||10,438||$25.50||$26.87||$25.50|
|14 Jul 2022||$26.00||$-0.83||-3.09%||34,803||$26.50||$26.50||$25.01|
|13 Jul 2022||$26.83||$0.03||0.11%||9,450||$26.79||$26.90||$26.50|
|12 Jul 2022||$26.80||$-0.90||-3.25%||14,374||$27.60||$28.00||$26.80|
|13 Jun 2022||Stephen (Steve) Denaro||Issued||40||$940,000|| |
Issue of options.
|13 Jun 2022||John Seaberg||Issued||80||$1,880,000|| |
Issue of options.
|13 Jun 2022||Wayne Paterson||Issued||300||$7,050,000|| |
Issue of options. As per announcement on 17-06-2022
|13 Jun 2022||Wenyi Gu||Issued||40||$940,000|| |
Issue of options.
|07 Mar 2022||Stephen (Steve) Denaro||Buy||2||$40,039|| |
|03 Dec 2021||John Seaberg||Exercise||7||$56,000|| |
Exercise of options.
|03 Dec 2021||John Seaberg||Buy||7||$56,000|| |
Exercise of options. As per announcement on 07/12/2021.
|Mr Stephen (Steve) Denaro||Company SecretaryNon-Executive Director||Oct 2018|| |
Mr Denaro was appointed as Non-Executive Director and Company Secretary on 31 October 2018. Mr Denaro has more than 30 years of senior level and Board level experience across publiclylisted companies; serving as Chief Financial Officer, Company Secretary and Director. He brings experience in managing compliance with finance and accounting regulatory requirements. He has managed investment acquisitions and subsequent funding (domestic and international). Mr Denaro is a resident of Brisbane, QLD, Australia.
|Mr John Seaberg||Non-Executive DirectorNon-Executive Chairman||Oct 2014|| |
Mr Seaberg has been an independent Non-Executive Director of Anteris Technologies Ltd since 10 October 2014. He was appointed as Deputy Chair on 16 June 2016 and Chair on 14 March 2017. From 2008 until its sale to Baxter in 2012, Mr Seaberg served as Chair of the Board of Synovis Inc (NASDAQ:SYNO), a Minneapolis based manufacturer of various medical devices and bio scaffold tissue products. From 2007 until 2014 he was Founder, Chair and CEO of NeoChord Inc., a venture capital-backed company commercialising technology developed at the Mayo Clinic for the repair of the mitral valve via minimally invasive techniques. From 1996 to 2006, Mr Seaberg served at Guidant Corp (subsequently acquired by Boston Scientific Corp) where he served in various executive level positions including Director of Bradycardia Marketing for Cardiac Rhythm Management, Vice President of Sales for Cardiac Surgery and Vice President of Sales for Cardiac Rhythm Management. In 1991, Mr Seaberg was co-founder of ACIST Medical and served as its first President and CEO. Mr Seaberg is a resident of Minneapolis, Minnesota, United States of America. He is a member of Risk Management Committee.
|Mr Wayne Paterson||Managing DirectorChief Executive Officer||Feb 2016|| |
Mr Paterson has been a Director of Anteris Technologies Ltd since 10 October 2014. Mr Paterson has held numerous senior positions in multi-national pharmaceutical companies and has lived in seven countries during the past 20 plus years. Throughout his career, he has been responsible for building and managing multi-billion dollar businesses throughout the world, including mergers, integrations, acquisitions and major restructures as President and CEO. From 2005 to 2013 Mr Paterson held senior positions at Merck KGaA, most recently as President of Europe, Canada and Australia. Prior to this, Mr Paterson was President of Emerging Markets, President of Japan and Global Head of Cardiovascular Medicine. Between 1999 and 2005, Mr Paterson served at Roche Pharmaceuticals where he was most recently Head of Pharmaceuticals in Roche's South Korean operation. He also served as Head of Commercial Operations for Roche China based in Shanghai. Mr Paterson is an Australian national and resides in Minneapolis, Minnesota, United States of America.
|Dr Wenyi Gu||Non-Executive Director||Oct 2018|| |
Dr Gu currently works as Research Fellow for the Australian Institute for Bioengineering and Nanotechnology at The University of Queensland (UQ), where he began his post-doctoral work in 2001. He held a Peter Doherty Fellowship (2006-2009) and was supported by the National Health and Medical Research Council (NHMRC) to work at Harvard Medical School, Harvard University as a visiting research fellow. Before engaging in nanomedicine (focusing on drug delivery and cancer therapy), he worked on RNAi-based gene therapy for several years at Translation Research Institute (TRI). Dr Gu's research has been published in respected industry journals such as Nature Communications, Ad. Materials, ACS Nano and PNAS USA. Dr Gu is a resident of Brisbane, QLD, Australia.
|Mr Matthew McDonnell||Chief Financial Officer|| |
|Mr David St Denis||Chief Operating Officer|| |
|Perceptive Life Sciences Master Fund Ltd||1,840,000||13.56%|
|CS Third Nominees Pty Limited <Hsbc Cust Nom Au Ltd 13 A/C>||1,310,115||9.66%|
|HSBC Custody Nominees (Australia) Limited A/C 2||876,687||6.46%|
|Citicorp Nominees Pty Limited||567,794||4.19%|
|Bnp Paribas Noms Pty Ltd <Global Markets Drp>||417,295||3.08%|
|Hunter Capital Advisors P/L||411,214||3.03%|
|Mr Patrick Chew||283,055||2.09%|
|Mr Ricky Steven Neumann||244,314||1.80%|
|Hsbc Custody Nominees (Australia) Limited||201,207||1.48%|
|Bnp Paribas Nominees Pty Ltd <Ib Au Noms Retailclient Drp>||189,221||1.39%|
|Amedan Pty Ltd||111,195||0.82%|
|Dr Gary Owen Rooke||111,000||0.82%|
|Mishtalem Pty Ltd||103,000||0.76%|
|Mr Daniel Bernard Clough||100,000||0.74%|
|Superior Coatings (Aust) Pty Ltd||100,000||0.74%|
|Evolution Capital Pty Ltd||95,000||0.70%|
|Bnp Paribas Nominees Pty Ltd Six Sis Ltd <Drp A/C>||89,033||0.66%|
|Mdm Leby Hwang||84,000||0.62%|
|Sisu International Pty Ltd||82,500||0.61%|
|Sean Barrett Pty Ltd <Super Fund A/C>||80,000||0.59%|